Novartis AG ADR (NVS): Price and Financial Metrics

Novartis AG ADR (NVS): $98.91

1.80 (+1.85%)

POWR Rating

Component Grades








Add NVS to Watchlist
Sign Up

Industry: Medical - Pharmaceuticals




#1 of 167

in industry

NVS Price/Volume Stats

Current price $98.91 52-week high $105.56
Prev. close $97.11 52-week low $74.09
Day low $97.89 Volume 3,739,700
Day high $98.93 Avg. volume 2,160,586
50-day MA $98.41 Dividend yield 2.36%
200-day MA $88.00 Market Cap 209.65B

NVS Stock Price Chart Interactive Chart >


  • Growth is the dimension where NVS ranks best; there it ranks ahead of 97.28% of US stocks.
  • NVS's strongest trending metric is Growth; it's been moving up over the last 157 days.
  • NVS ranks lowest in Momentum; there it ranks in the 16th percentile.

NVS Stock Summary

  • NVS has a market capitalization of $209,762,910,000 -- more than approximately 99.31% of US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, NOVARTIS AG is reporting a growth rate of -65.83%; that's higher than merely 20.95% of US stocks.
  • NOVARTIS AG's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 9.58%, greater than the shareholder yield of 81.54% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to NOVARTIS AG, a group of peers worth examining would be PFE, CSCO, ABBV, NFLX, and SAP.
  • Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to

NVS Valuation Summary

  • In comparison to the median Healthcare stock, NVS's price/sales ratio is 21.57% lower, now standing at 4.
  • NVS's EV/EBIT ratio has moved up 8.4 over the prior 243 months.

Below are key valuation metrics over time for NVS.

Stock Date P/S P/B P/E EV/EBIT
NVS 2023-05-23 4.0 4.0 29.9 24.5
NVS 2023-05-22 4.0 4.1 30.1 24.6
NVS 2023-05-19 4.0 4.1 30.1 24.6
NVS 2023-05-18 4.0 4.0 30.0 24.5
NVS 2023-05-17 4.1 4.1 30.2 24.7
NVS 2023-05-16 4.1 4.1 30.7 25.1

NVS Growth Metrics

    Its 2 year revenue growth rate is now at 6.14%.
  • Its year over year net income to common stockholders growth rate is now at 204.01%.
  • Its 2 year net cashflow from operations growth rate is now at 6.18%.
Over the past 70 months, NVS's revenue has gone up $2,417,000,000.

The table below shows NVS's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-12-31 51,828 14,236 6,955
2022-09-30 52,263 14,009 21,797
2022-06-30 52,788 14,213 22,982
2022-03-31 52,997 14,590 24,184
2021-12-31 52,877 15,071 24,021
2021-09-30 52,385 15,192 9,807

NVS's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NVS has a Quality Grade of B, ranking ahead of 86.01% of graded US stocks.
  • NVS's asset turnover comes in at 0.42 -- ranking 108th of 682 Pharmaceutical Products stocks.
  • GHSI, KALA, and ADAP are the stocks whose asset turnover ratios are most correlated with NVS.

The table below shows NVS's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.420 0.693 0.212
2021-06-30 0.406 0.691 0.194
2021-03-31 0.393 0.691 0.176
2020-12-31 0.392 0.697 0.182
2020-09-30 0.401 0.700 0.174
2020-06-30 0.412 0.699 0.180

Novartis AG ADR (NVS) Company Bio

Novartis AG is a Swiss-American multinational pharmaceutical corporation based in Basel, Switzerland and Cambridge, MassachusettsUnited States (global research). It is one of the largest pharmaceutical companies in the world. (Source:Wikipedia)

NVS Latest News Stream

Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream

Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about NOVARTIS AG that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Why Is AVROBIO (AVRO) Stock Up 83% Today?

AVROBIO (AVRO) stock is seeing massive gains on Monday as the company sells one of its gene therapies to Novartis (NVS).

William White on InvestorPlace | May 22, 2023

AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab

The FDA approves AbbVie's (ABBV) epcoritamab, to be marketed as Epkinly, for relapsed/refractory large B-cell lymphoma, a form of NHL. Epkinly is AbbVie's third blood cancer drug.

Yahoo | May 22, 2023

Novartis (NVS) Up 10.8% YTD on Strong Q1, Pipeline Progress

Novartis (NVS) gains 10.6% year to date on strong first-quarter results and encouraging data on Kisqali from the NATALEE study.

Yahoo | May 19, 2023

Novartis CEO: Some Cancer Drugs Dropped From Pipeline Because of Medicare Price Negotiations

Medicare’s new ability to negotiate some drug prices is a "super high concern," according to CEO Vas Narasimhan.

Yahoo | May 19, 2023

Why Novartis (NVS) is a Top Dividend Stock for Your Portfolio

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Novartis (NVS) have what it takes? Let's find out.

Yahoo | May 19, 2023

Read More 'NVS' Stories Here

NVS Price Returns

1-mo -5.46%
3-mo 20.08%
6-mo 11.79%
1-year 14.10%
3-year 24.77%
5-year 67.62%
YTD 12.09%
2022 6.47%
2021 -5.12%
2020 2.08%
2019 28.03%
2018 5.95%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!